JZ
Insider
Jonathan Zalevsky
Chief R&D OfficerJonathan Zalevsky (Chief R&D Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Nektar Therapeutics (NKTR). The largest single filing was $398K of NKTR (5,681 sh × $70.00, as filed), executed Jun 30.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$872K
shares × price, as filed
Last traded
Jun 30
Filed Jul 2
Median ADV $69.7M across their filed names
Open performance→Volume by month
Buys $0
Sells $872K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
NKTRRecent filings
NKTRSALE
Nektar Therapeutics
View filing →
$398K5,681 sh × $70.00
Exec Jun 30
Filed Jul 2 · 7:06 PM ET NKTRSALE Nektar Therapeutics View filing → $336K
5,538 sh × $60.71
Exec Jun 15
Filed Jun 17 · 5:30 PM ET NKTRSALE Nektar Therapeutics View filing → $138K
3,867 sh × $35.67
Exec Jan 20
Filed Jan 22 · 5:30 PM ET